NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes

NCT04596631

CompletedPhase 3

Sponsor: Novo Nordisk A/S

Conditions: Diabetes Mellitus, Type 2

Interventions: Oral semaglutide, Placebo (semaglutide)

Countries: United States, Australia, Austria, Belgium, Czechia, Greece, India, Israel

This study compares 2 medicines for type 2 diabetes: semaglutide (new medicine) and a dummy medicine (placebo). Semaglutide will be tested to see how well it works compared to the dummy medicine. The study will also test if semaglutide is safe in children and teenagers. Participants will either get semaglutide or the dummy medicine - which one is decided by chance. Participants will take 1 tablet of the study medicine every morning on an empty stomach. They have to wait 30 minutes before they eat, drink or take any other medication by mouth. The study will last for about 1 year and 3 months (66 weeks). Participants will have 12 clinic visits and 8 phone calls with the study doctor. At all 12 clinic visits, participants will have blood samples taken. Participants will also be asked some questions.

Eligibility overview

Sex: ALL

Age: 10 Years to 18 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Informed consent from parent(s) or legally acceptable representative (LAR) and child assent from the subject obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial.
* Male or female, aged 10 to below 18 years at the day of randomisation
* HbA1c 6.5%-11.0% (47-97 mmol/mol) (both inclusive)
* Diagnosed with type 2 diabetes mellitus according to the American Diabetes Association criteria and treated with:
* stable metformin dose (stable metformin dose is defined as at least 1000 mg daily or the maximum tolerated dose for 56 days or longer prior to screening) or
* stable metformin dose and a stable dose of basal insulin (stable dose of basal insulin is defined as basal insulin treatment equal to or more than 30 days prior to screening, compared to the dose at screening, dose adjustments of ± 25% are allowed) or
* stable dose of basal insulin

Exclusion Criteria:

* Diagnosis of type 1 diabetes
* Maturity onset diabetes of the young (MODY)
* Positive insulinoma associated-protein 2 (IA-2) antibodies or anti-glutamic acid decarboxylase (anti-GAD) antibodies.

Locations (97)

Birmingham, Alabama, United States
Los Angeles, California, United States
New Haven, Connecticut, United States
Jacksonville, Florida, United States
Pensacola, Florida, United States
Tampa, Florida, United States
Atlanta, Georgia, United States
Columbus, Georgia, United States
Indianapolis, Indiana, United States
Louisville, Kentucky, United States
Baton Rouge, Louisiana, United States
Baltimore, Maryland, United States
Jackson, Mississippi, United States
Buffalo, New York, United States
Pittsburgh, Pennsylvania, United States
Rapid City, South Dakota, United States
Nashville, Tennessee, United States
Amarillo, Texas, United States
San Antonio, Texas, United States
San Antonio, Texas, United States
Charlottesville, Virginia, United States
Richmond, Virginia, United States
Richmond, Virginia, United States
Gosford, New South Wales, Australia
Westmead, New South Wales, Australia
North Adelaide, South Australia, Australia
Clayton, Victoria, Australia
Parkville, Victoria, Australia
Nedlands, Western Australia, Australia
Salzburg, Austria
+ 67 more on CT.gov